Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Muscle synergies in de novo Parkinson's disease: towards the development of a motor pre-clinical biomarker.

FY 2013-14

Summary
Parkinson's disease (PD) is a progressive neurodegenerative disease that affects millions of individuals worldwide. PD is associated with motor symptoms such as tremor, rigidity, slowness of movements, and postural instability. One of the main issues with the treatment of PD is that it can only be diagnosed clinically after a great majority of dopamine neurons of the basal ganglia have degenerated. While there are non-motor symptoms of PD that can be present prior to the hallmark motor symptoms, these are non-specific to PD and not related to dopamine deficiency. Recently, studies showed that motor behaviors are mediated by linear combinations of muscle synergies, or groups of muscles, activated together as independent movement modules. These synergies were proposed to be organized in the brainstem and spinal cord, and activated by supra-spinal structures. It is well known that the basal ganglia play a major role in the control of motor behavior by promoting voluntary movements and inhibiting involuntary ones. The basal ganglia should then be involved in the activation of muscle synergies. Interestingly, spatial and temporal properties of muscle synergies were shown to be sensitive to cortical damage and plasticity in stroke patients. Since dopamine neuron degeneration will alter basal ganglia activity in PD, we hypothesize that there will be alterations in muscle synergy properties, even before the presence of clinical motor symptoms. To address this, we will evaluate upper and lower-limb muscle synergies in patients recently diagnosed with PD presenting with motor symptoms only on one side of the body. We will compare muscle synergy properties between the affected and non-affected side, as well as with age and gender-matched healthy controls. Using well established data and statistical analyses, we will be able to determine which muscle synergy properties inform us about dopamine deficiency in the basal ganglia prior to the appearance of motor symptom.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
300902
Name
Daneault Jean-François
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Muscle synergies in de novo Parkinson's disease: towards the development of a motor pre-clinical biomarker.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Basal Ganglia; Biomarker; Dopamine; Motor; Muscle Synergy; Non-Negative Matrix Factorization; Parkinson; Plasticity; Pre-Clinical
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disease that affects millions of individuals worldwide. PD is associated with motor symptoms such as tremor, rigidity, slowness of movements, and postural instability. One of the main issues with the treatment of PD is that it can only be diagnosed clinically after a great majority of dopamine neurons of the basal ganglia have degenerated. While there are non-motor symptoms of PD that can be present prior to the hallmark motor symptoms, these are non-specific to PD and not related to dopamine deficiency. Recently, studies showed that motor behaviors are mediated by linear combinations of muscle synergies, or groups of muscles, activated together as independent movement modules. These synergies were proposed to be organized in the brainstem and spinal cord, and activated by supra-spinal structures. It is well known that the basal ganglia play a major role in the control of motor behavior by promoting voluntary movements and inhibiting involuntary ones. The basal ganglia should then be involved in the activation of muscle synergies. Interestingly, spatial and temporal properties of muscle synergies were shown to be sensitive to cortical damage and plasticity in stroke patients. Since dopamine neuron degeneration will alter basal ganglia activity in PD, we hypothesize that there will be alterations in muscle synergy properties, even before the presence of clinical motor symptoms. To address this, we will evaluate upper and lower-limb muscle synergies in patients recently diagnosed with PD presenting with motor symptoms only on one side of the body. We will compare muscle synergy properties between the affected and non-affected side, as well as with age and gender-matched healthy controls. Using well established data and statistical analyses, we will be able to determine which muscle synergy properties inform us about dopamine deficiency in the basal ganglia prior to the appearance of motor symptom.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Daneault, Jean-François
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2013-14) | Canada Spends